Finally good news! The anti-inflammatory drug colchicine is effective in the treatment of COVID-19 and reduces the risk of complications caused by this disease.
This is the result of a study by doctors at the Montreal Institute of Cardiology (MHI).
According to the doctors themselves, the results are a “great scientific discovery” and make colchicine the “first orally administered drug in the world” that can be used to treat patients with COVID-19 whose condition does not require hospitalization.
According to the study, the use of colchicine, used mainly for the treatment of gout, an arthritic joint disease, reduced by 21 percent the risk of death or hospitalization of people with COVID-19, compared with the group receiving so-called placebo.
The study was conducted in Canada, the United States, Europe, and South America and involved 4,488 people with COVID-19 who were not hospitalized at the time of enrollment and had at least one risk factor that could lead to complications with the course of the disease.
The drug helped
In 4,159 of whom were diagnosed with COVID-19 by PCR, colchicine reduced the risk of hospitalization by 25 percent, the need for pulmonary ventilation by 50 percent, and the risk of death by 44 percent. The MHI said it was the largest study “testing an oral drug” in non-hospitalized people with COVID-19.
The study director, Canadian cardiologist Jean-Claude Tardif, who is also the director of the MHI Research Center, said that colchicine is effective in preventing dangerous inflammatory syndrome called so-called inflammatory syndrome. cytokine storms, as well as in reducing the complications associated with COVID-19. >
“We are pleased to offer the world’s first oral drug, the use of which could have a significant impact on public health and potentially prevent the complications associated with COVID-19 in millions of patients,” Tardif said.
It happened in the world
Source: Dnes24.sk by www.dnes24.sk.
*The article has been translated based on the content of Dnes24.sk by www.dnes24.sk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!